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Abstract: 
Background: HTLV–1 or 2 co–infection in individuals infected with HIV–1 can lead to increased 
morbidity. The shared routes of transmission of HTLV with HIV–1 may increase the prevalence of 
HTLV among HIV–1 infected population and subsequently affect patient’s management.  
Methods: Sera were collected from 144 HIV–1 infected individuals attending the highly active 
anti–retroviral therapy (HAART) clinic of the University of Ilorin Teaching Hospital between the 
months of May and August 2016. Sera were tested for anti–HTLV IgM and IgG antibodies to HTLV–
1&2 using the sandwich enzyme–linked immunosorbent assay.  
Results: Out of the 144 participants tested, 47 (32.6%) and 37 (25.7%) were positive for HTLV 
IgG and IgM respectively. Twenty–one participants (14.6%) had both IgG and IgM antibodies to 
HTLV–1&2. Ten individuals were anti–retroviral drug naïve out of which, four and six were positive 
to anti–HTLV IgG and IgM respectively.  
Conclusion: Findings from this study revealed that there is high sero–prevalence of HTLV IgG and 
IgM antibodies among HIV–1 sero–positive individuals in Ilorin. The high rate of co–infection 
supports routine screening for HTLV–1/2 co-infection among HIV–1 infected individuals in Ilorin, 
Nigeria so that the purpose of HAART treatment and monitoring of patients to prevent progression 
to AIDS will not be aborted. 
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Abstrait: 
Contexte: La co-infection par le HTLV-1 ou 2 chez les personnes infectées par le VIH-1 peut 
entraîner une morbidité accrue. Les voies de transmission partagées du VIH-1 par le VIH-1 
peuvent augmenter la prévalence du virus dans les populations infectées par le VIH-1 et, par 
conséquent, affecter la prise en charge du patient. 
Méthodes: Des sérums ont été recueillis auprès de 144 personnes infectées par le VIH-1 
fréquentant la clinique de traitement antirétroviral hautement actif (HAART) de l'hôpital 
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universitaire de Ilorin entre mai et août 2016. Les sérums ont été testés pour la détection des IgM 
et IgG anti-HTLV. anticorps anti-HTLV-1 et 2 en utilisant l’essai sandwich immuno-absorbant lié à 
une enzyme. 
Résultats: Sur les 144 participants testés, 47 (32,6%) et 37 (25,7%) étaient positifs pour les IgG 
et les IgM du HTLV, respectivement. Vingt et un participants (14,6%) avaient à la fois des 
anticorps IgG et IgM anti-HTLV-1 et 2. Dix personnes n'avaient jamais reçu d'antirétroviraux, dont 
quatre et six étaient positives aux IgG et aux IgM anti-HTLV, respectivement. 
Conclusion: Les résultats de cette étude ont révélé une prévalence élevée de l'anticorps IgG et 
IgM du HTLV chez les sujets séropositifs pour le VIH-1 à Ilorin. Le taux élevé de coïnfection 
favorise le dépistage systématique de la co-infection par HTLV – 1/2 chez les personnes infectées 
par le VIH – 1 à Ilorin, au Nigéria, de sorte que l'objectif du traitement HAART et du suivi des 
patients pour prévenir la progression du sida ne soit pas avorté. 
Mots-clés: Virus lymphotrophe humain à cellules T, Virus de l'immunodéficience humaine-1, IgG, 
IgM, Compte de CD4+ 
Introduction: 
 Human T-lymphotrophic viruses 
(HTLV) and human immunodeficiency 
viruses (HIV-1) are two distinct family 
members of Retroviridae causing 
significant infections worldwide. These 
viruses have common modes of 
transmission and share an in vivo 
tropism for cells of the immune system 
particularly T lymphocytes, resulting into 
co–infections of a number of individuals 
worldwide (1, 2). HTLV is made up of 
two major types associated with disease 
in humans which are HTLV-1 and HTLV-
2. Two other types have been 
discovered which are HTLV-3 and HTLV-
4 (3). HTLV-1 is endemic in many well–
defined geographic areas like Sub– 
Saharan Africa in which Nigeria is 
included. However, there is no recent 
representative data regarding 
prevalence of HTLV-1 among HIV-1 
infected individuals in Nigeria but 
majority of serological studies carried 
out were on blood donors (4–8). 
Research has shown that HIV-1/HTLV-1 
and HIV-1/HTLV-2 co-infection probably 
occur more frequently than physicians 
are aware of since routine testing for 
HTLV-1/2 is not usually performed. 
 HIV-1 infection is sexually 
transmitted therefore people with HIV–1 
disease are at risk of having HTLV 
infection because both have same routes 
of transmission and similar cell tropism. 
Therefore, co–infection of both viruses 
will likely influence the pattern of 
progression to AIDS, since both viruses 
preferentially infect CD4+ T-cells. The 
common link between HTLV–1/2 in HIV–
1 patients is that both have been linked 
normal or high CD4+ T cell count hinder 
proper treatment as a result of delay in 
introduction of highly active anti–
retroviral therapy (HAART) in co–
infected patients. It has also been 
reported that co–infection of HTLV–1/2 
and HIV–1, may accelerate progression 
to AIDS and significantly shorten 
survival time in such individual (9). 
 A major issue in developing 
countries including Nigeria is lack of 
routine screening practice for HTLV, thus 
there exist gaps in knowledge and 
awareness of transmission of HTLV 
infection from both healthy individuals 
and those who are co–infected with HIV–
1. Little is known about the pattern of 
sero-prevalence of HTLV–1 in Ilorin; this 
study is therefore designed to determine 
the sero-prevalence of HTLV–1 among 
HIV–1 infected individuals attending the 
HAART clinic of UITH, Ilorin  
Materials and method: 
Study design and participants 
 This descriptive cross–sectional 
study was conducted at the HAART clinic 
among HIV–1 positive patients 18 years 
and above that visited University of 
Ilorin Teaching Hospital (UITH), Ilorin, 
Kwara State, Nigeria. At the HAART 
clinic, diagnoses of new cases of HIV 
infection are made and over 4 000 HIV–
1/AIDS patients on therapy are 
monitored. 
Sample size determination 
 Sample size was estimated using 
fisher’s formula (10) adopting a 
prevalence rate of 10.47% (11) as 
follows; N = Z2pq/d2 where ‘N’ is the 
required sample size, ‘Z’ is the 
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confidence interval at 95% (1.96), ‘p’ is 
estimated prevalence of HIV–1 Infection, 
‘q’ is 1 – p, and ‘d’ is the degree of 
accuracy set at 0.05. This gives a 
sample size of 144. Patients were 
consecutively recruited after giving 
informed consents. Under aseptic 
conditions, 5 ml of venous blood was 
collected from each consenting 
participant using a hypodermic needle. 
Aliquots of blood specimen were 
decanted into tubes without 
anticoagulant and EDTA anti-coagulated 
tubes to determine the CD4 count. The 
blood sample bottles were labeled with 
sample code L001– L144.  
 Serum from blood samples in 
tubes without anticoagulant were 
separated by allowing the blood to clot 
at room temperature, and then 
centrifuged at 2500 rpm for 10 minutes. 
The serum samples were transferred 
into cryovials and stored at –20 oC until 
required for analysis.  The serum 
samples were analyzed for IgM and IgG 
antibodies to HTLV using enzyme–linked 
immunosorbent assay based on 
manufacturer’s instruction. 
Determination of CD4+ T–cell count in 
peripheral blood of HIV–1 patients 
 The CD4 T–cell count 
enumeration was done within 6 hours of 
blood specimen collection in HAART 
clinic laboratory in UITH. The blood 
sample dispensed inside the EDTA anti-
coagulated tubes was used to determine 
the CD4 T–cell count in whole blood 
using Partec Cytoflow analyser (12).  
 
Determination of anti–HTLV IgM and IgG 
antibodies in serum of HIV–1 patients  
 Analysis of IgG and IgM 
Antibodies to HTLV were detected using 
human T–lymphotrophic virus sandwich 
ELISA. The micro–ELISA strip plates 
were pre–coated with an antigen specific 
to HTLV IgG and IgM antibodies 
respectively. Standards test samples 
were added to appropriate micro–ELISA 
strip plate wells and combined to specific 
antigen. Then a horseradish peroxidase 
(HRP)–conjugated antigen specific to 
HTLV was added to each micro–ELISA 
strip plate well and incubated. Free 
components were washed away. The 
TetraMethylBenzidine (TMB) contained 
HTLV substrate solution was added to 
each well. Only those wells that 
contained HTLV–IgG or IgM in different 
micro–ELISA strip plate respectively and 
HRP conjugate HTLV antigen appeared 
blue in colour and then yellow after 
addition of the stop solution. The optical 
density (O.D) was measured using a 
spectrophotometer at a wavelength of 
450nm. The presence of anti–HTLV IgG 
or IgM antibodies in different micro–
ELISA strip plate, respectively, was 
determined by comparing the O.D of 
sample to CUT OFF value of the plate 
according to manufacturers’ instruction. 
 
Statistical analysis   
 Data entry and analysis was 
carried out using the Epi info version 
7.14 (2014) software packages (CDC). 
Results were presented in tables and 
charts. Chi–square test was used for 
statistical significance of the difference 
for different variables respectively.  p 
value of < 0.05 was  regarded as 
significant.  
Ethical Considerations 
 This study was conducted in 
compliance with the Helsinki Declaration 
of 1975, as revised in 2008 and was 
approved by the Health Research and 
Ethics Committee of the University of 
Ilorin Teaching Hospital (ERC 
PAN/2016/04/1532). The participants 
gave their written informed consent 
before they were enrolled in the study. 
All data were analyzed anonymously 
throughout the study. 
Results: 
 A prevalence of 47 (32.6%) and 
37 (25.7%) was reported for IgM and 
IgG antibodies to HTLV respectively in 
the study population. The prevalence of 
anti–HTLV IgG and IgM antibodies 
among HIV–1 patients in different age 
groups showed that more individuals 
within age group of 40–49 years had 
more anti–HTLV IgG and IgM antibodies 
as shown in Figure 1.  
 Both IgG and IgM antibodies to 
HTLV were detected together in 21 HIV–
1 patients among the different age 
groups. Among those between 30–39 
years, six individuals had both IgG and 
IgM antibodies to HTLV, while among 
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age group 40–49 years, 10 individuals 
had both IgG and IgM antibodies to 
HTLV, and also among age group 50–59 
years, three individuals had both IgG 
and IgM antibodies to HTLV and in the 
age group greater than 60 years, two 
persons had both IgG and IgM 
antibodies to HTLV. Of the 144 HIV–1 
seropositive patients recruited in this 
study, 40 (27.8%) were males and 104 
(72.2%) were females. The females 
recruited in the study had HTLV IgG and 
IgM antibody than the males as shown 






















































Male 40 12 (30) 9 (22.5) 4 
Female 104 35 (33.7) 28 (26.9) 17 
Chi-square  0.175 0.296  
p value  0.675 0.586  




Human T-lymphotrophic virus 1/2 and HIV infections  
206 
 
 The distribution of HTLV IgG and 
IgM Antibodies by CD4 grouping among 
HIV–1 seropositive patients at UITH 
revealed that a number of participants 
with CD4 cell count below 200 cell/mm3 
had IgG and IgM antibodies to HTLV but 
with a low frequency while individuals 
whose CD4 cell count was above 
200cell/mm3, had a high possibility of 
producing detectable IgG and IgM 
antibodies to HTLV. The CD4+ T–cell 
count of individuals that IgM antibodies 
to HTLV has been detected when 
compared to individuals not infected 
with HTLV is not significant as shown in 
Table 2. 
 
Table 2: Distribution of HTLV IgG and IgM antibodies by CD4 grouping among HIV-1 seropositive patients at UITH 
CD4 grouping Total %IgG+ %IgM+ 
≤ 200 40 9 (22.5) 7 (17.5) 
>200 104 38 (36.5) 30 (28.8) 
Chi-square  2.589 1.948 
p-value  0.108 0.163 
Total 144 47 (32.6) 37 (25.7) 
 
 Table 3 shows sero–prevalence of 
HTLV IgG and IgM antibodies among 
HIV–1 sero-positive patients by ART 
status. Participants not on ART but sero-
positive for HTLV IgG are more than 
those not on ART but sero-positive for 
HTLV IgM. 
Table 3: Sero-prevalence of HTLV infection among HIV-1 seropositive individuals by ART drug status 
HAART drugs Total IgG+ (%) IgM+ (%) 
Yes 134 41 (30.6) 33 (24.6) 
No 10 6 (60) 4 (40) 
Chi-square  3.659 1.152 
p-value  0.056 0.283 




 In this study, an overall sero–
prevalence of 32.6% and 25.7% was 
reported for anti–HTLV IgG and IgM 
antibodies respectively in HIV–1 infected 
individuals in UITH, Ilorin. Fourteen 
percent of the study participants had 
both IgG and IgM antibodies to HTLV, 
which is an indication that this group has 
been recently infected with HTLV and 
are at the point of seroconversion. Only 
16 participants with IgM antibodies to 
HTLV can be said to be recently infected 
among the participants recruited. This 
observation is not conclusive because 
there was lack of information on time of 
onset of HIV–1 and HTLV infection but 
we can suggest that HTLV infection 
acquired is a marker of high risk 
behavior that might be associated with 
exposures to HIV–1.   
 In our study, we discovered that 
higher percentage of the participants 
infected were females, with 33.6% and 
26.9% of them having IgG and IgM 
antibodies to HTLV respectively. 
Although, the number of females 
recruited in this study was more than 
the males, this could be because there is 
more efficient transmission from men to 
women during sexual intercourse. The 
HTLV sero–prevalence among HIV-
infected individuals in this study is 
higher than the prevalence reported in 
previous studies, and this may be 
adduced to the reluctance in adapting to 
behaviours that are less risky especially 
amongst those with HIV in Ilorin. Also, 
the high sero–prevalence rate may be as 
a result of the method employed in this 
study.  Nasir et al. (13) reported an 
overall sero–prevalence of 4.9% for 
HIV–1/HTLV co–infection among ART 
naïve patients in Abuja. In Brazil, HTLV–
1 prevalence of 1.9% was reported in 
HIV–1 patients using the Polymerase 
Chain Reaction assay (14). Rego et al. 
(15) reported the prevalence of 
HTLV/HIV–1 co–infection to be 1.8% in 
KwaZulu–Natal, South Africa. In another 
study conducted in rural Guinea–Bissau 
among HIV–1 and HIV–2–infected 
women, overall HTLV–1 prevalence of 
5.2% was reported (16). The difference 
is most likely due to the difference in the 
design, population and method of 
detection of HTLV. Molecular methods 
were used to confirm HTLV proviral DNA 
in the studies mentioned, whereas 
antibody detection was solely used in 
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this study.     
 In our study, the highest 
prevalence of HTLV IgG and IgM 
antibodies was among age group 40–49 
years. This was in contrast with Nasir et 
al. (13) study who reported highest 
prevalence of HTLV–1 among age group 
21–30 years. This could be due to the 
fact that the population of those mostly 
recruited falls among this age group in 
our study. Also, there is a presumption 
that the accumulation of sexual 
exposures with age in women of this 
population might contribute to the 
results obtained in this study. 
 Thirty out of 37 patients with IgM 
antibodies to HTLV had CD4+ 
lymphocyte count more than 200 
cells/mm3 in our study, which is an 
indication that co–infected individuals 
may present with a seemingly normal 
CD4+ cell counts that may not correctly 
reflect the true immune status of the 
individual. We cannot interpret in clear 
terms that the seven individuals with 
CD4+ lymphocyte count less than 200 
cells/mm3 who produced IgM antibodies 
to HTLV is associated with HIV–1 
immune status of the individuals. In this 
scenario the immune system will be 
incompetent to produce neutralizing 
antibodies since HIV–1 infection can also 
lead to extensive defects in the humoral 
arm of the immune system (17).  
 There are reports that CD4+ 
lymphocyte count cannot always be 
considered a reliable marker of 
immunological competence in HIV–1 
infected people, especially in patients 
co–infected with HTLV (3, 18, 19). There 
was no significant association between 
CD4+ cell count in HTLV/HIV–1 co–
infected patients compared to HIV–1 
infected individuals (p=0.163). CD4+ 
cell count is one of the important criteria 
used to determine eligibility for HAART 
in HIV–1–infected individuals especially 
in resource–limited settings nevertheless 
in the event of HTLV/HIV–1 co–
infections, CD4 cell counts may not be 
reliable.  
Conclusion:  
 Our findings in this study 
revealed that there is high sero–
prevalence of HTLV IgG and IgM among 
HIV–1 sero–positive patients in UITH. 
The high rate of co–infection supports 
routine screening for HTLV–1/2 co-
infection among HIV–1 infected 
individuals in Ilorin, Nigeria so that the 
purpose of HAART treatment and 
monitoring of patients to prevent 
progression to AIDS will not be aborted.
 Treatment modality in individuals 
co–infected with HIV–1 and HTLV–1/2 is 
recommended because these patients 
present normal or unexpectedly high 
CD4+ T cell counts which does not 
account for the immunosuppression 
experienced.  
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